Generic drugs can seem like lifesavers for people in need of medicine. They cost less than the name-brand drugs with the same formulation, and insurance plans tend to steer patients to them for that reason. The need for generic drugs has never been more important as we live through a pandemic and all the health ramifications affecting those who have contracted Covid-19. As individuals, the healthcare industry, and governments look contain the costs of Covid, one place they are all turning to are generic drugs. The Association for Accessible Medicines (AAM), the trade association of generic and biosimilar manufacturers, recently released a report detailing the financial benefit of generic and biosimilar drugs to American patients.
Dan Leonard, President and Chief Executive Officer of the Association for Accessible Medicines (AAM) shares more on what we need to know.
For more information: AccessibleMeds.org